Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody.
about
The development of immunoconjugates for targeted cancer therapyEngineered Nanoparticles Against MDR in Cancer: The State of the Art and its Prospective.Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancerEnhanced antitumor efficacy and reduced systemic toxicity of sulfatide-containing nanoliposomal doxorubicin in a xenograft model of colorectal cancerImproved efficacy and reduced toxicity of doxorubicin encapsulated in sulfatide-containing nanoliposome in a glioma modelRecent trends in multifunctional liposomal nanocarriers for enhanced tumor targetingExploiting the Metal-Chelating Properties of the Drug Cargo for In Vivo Positron Emission Tomography Imaging of Liposomal Nanomedicines.Landscape phage fusion protein-mediated targeting of nanomedicines enhances their prostate tumor cell association and cytotoxic efficiencyPreparation of RGD-modified long circulating liposome loading matrine, and its in vitro anti-cancer effects.B7-H3 overexpression in pancreatic cancer promotes tumor progression.Quantum dot loaded immunomicelles for tumor imaging.Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinicPharmacokinetics and tissue distribution profile of icariin propylene glycol-liposome intraperitoneal injection in mice.Nanomedicine: towards development of patient-friendly drug-delivery systems for oncological applicationsNANOMATERIALS FOR PROTEIN MEDIATED THERAPY AND DELIVERY.Evaluation of multivalent, functional polymeric nanoparticles for imaging applications.Prevention of metastasis in a 4T1 murine breast cancer model by doxorubicin carried by folate conjugated pH sensitive polymeric micelles.Intratumoral drug delivery with nanoparticulate carriers.Effective colon cancer prophylaxis in mice using embryonic stem cells and carbon nanotubesα-Enolase-binding peptide enhances drug delivery efficiency and therapeutic efficacy against colorectal cancer.Advancement and applications of peptide phage display technology in biomedical scienceBiological rationale for the design of polymeric anti-cancer nanomedicines.Cancer cell spheroids as a model to evaluate chemotherapy protocols.Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model.(89)Zr-labeled paramagnetic octreotide-liposomes for PET-MR imaging of cancerDesign of targeted cardiovascular molecular imaging probes.Small-molecule delivery by nanoparticles for anticancer therapyExtracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery.Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models.Liposomal cancer therapy: exploiting tumor characteristics.Receptor-targeted nanocarriers for therapeutic delivery to cancer.Theranostic applications of nanomaterials in cancer: drug delivery, image-guided therapy, and multifunctional platforms.Bioceramics: from bone regeneration to cancer nanomedicine.Challenges in development of targeted liposomal therapeutics.Immunoconjugates and long circulating systems: origins, current state of the art and future directionsThermosensitive liposomal drug delivery systems: state of the art review.Impact of wall shear stress and ligand avidity on binding of anti-CD146-coated nanoparticles to murine tumor endothelium under flow.The synthetic peptide CIGB-300 modulates CK2-dependent signaling pathways affecting the survival and chemoresistance of non-small cell lung cancer cell linesAnti-Tumor Effects of Bak-Proteoliposomes against Glioblastoma.Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives.
P2860
Q27021990-E77C7F6D-95A2-4E20-96C0-446D6A128ED3Q28073956-EFBFDD0C-6182-4000-8807-AFAC1EFCD6EDQ28480835-B8806BEF-A552-4D14-AC7D-FF5F42B606E7Q28484922-47084451-F8A1-4444-8E6B-E660A28A8FDBQ28541327-1A748A04-5BC3-4825-B557-78311E69B888Q30456053-F4DAADB5-D204-44C2-9982-8C63BAF17F30Q30829681-17C07D19-F9EA-49DB-8532-2BCA7DF51674Q33529963-0E990E4E-1A83-4583-B9E7-81D9885F5460Q33623605-D5EF6624-23F4-4959-95EE-5411332386A2Q33703916-F7F18C0F-2623-4B4D-AEB7-6FB9E0F64D82Q33721349-5C9EF1EC-9315-415C-AA9C-723621886C3CQ33911056-DCA9136F-665B-45AB-A938-911182B49C25Q34119355-E9EF60D2-64BA-44A1-A3DE-239049A26C73Q34259986-685A7EF5-7822-46A4-B34D-E7C3778C36F8Q34534023-51D41C97-4C8F-4302-9E92-F60F91246906Q34594347-9DC50FC5-7DFA-44DB-9C61-2A1DE182837CQ35023993-74717A11-9B12-4362-BC4A-84A16150A806Q35091415-60573AC8-03DA-4351-B25B-3287412D3945Q35234708-1574045F-CA0C-4180-9A8F-9D84BF3C8361Q35652276-E98763C9-FD4A-4DD6-8ED6-8A59DAC8FDF4Q35898339-928E7B65-793E-4ADC-972E-46857930AB90Q36160333-B155F0EE-9B4C-4FAA-869E-FC400AAD9050Q36312156-BED03B5F-C389-4CB7-AB6A-8C65A8AD5BFAQ36412928-85D16141-6CE4-41B5-B6BC-9A999DC0CCA1Q36625800-709CB359-B4FB-4574-9BDA-8286766F36D7Q36777401-DB753C95-868A-4D50-862A-EAFBD4AD5845Q37059874-35EBAA80-D619-43BE-8CDD-1C06833FE4BFQ37444094-BE502B8B-C0DE-45E3-A026-9DB0D91DBCA2Q37610100-8FA7264E-52DC-4E2F-93AB-14B5F2C2DA6BQ37679954-18370291-8257-493A-9E0A-1CF667502DE1Q37804383-46DC5F7B-F721-4161-804E-6329B90ED9DDQ37938830-9C39E791-7892-48E7-813E-D405E4ED93F0Q37947163-5D86420E-496D-4A4C-AC43-07BFA767B33FQ37993466-30CF3643-5836-4F7E-877A-A9FD30990793Q38042256-5B95B335-BEA9-4B83-AB59-D3C9BAE04A24Q38254572-A7FED265-7DAC-4931-8AB8-A10BEFBEAA8DQ38261727-2CF72D8C-9EBE-4B9E-844D-F0966D4B4826Q38709045-9795F593-C7B2-481A-8F70-DC722EBF309FQ38837839-92454B32-1626-4A4D-8A2B-D4A43F6A55FCQ38854876-7018075A-EFC7-4402-BC01-FCB432A0DE63
P2860
Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tumor-targeted nanomedicines: ...... -specific monoclonal antibody.
@en
Tumor-targeted nanomedicines: ...... -specific monoclonal antibody.
@nl
type
label
Tumor-targeted nanomedicines: ...... -specific monoclonal antibody.
@en
Tumor-targeted nanomedicines: ...... -specific monoclonal antibody.
@nl
prefLabel
Tumor-targeted nanomedicines: ...... -specific monoclonal antibody.
@en
Tumor-targeted nanomedicines: ...... -specific monoclonal antibody.
@nl
P2860
P1476
Tumor-targeted nanomedicines: ...... -specific monoclonal antibody.
@en
P2093
Tamer A ElBayoumi
Vladimir P Torchilin
P2860
P304
P356
10.1158/1078-0432.CCR-08-2392
P407
P577
2009-03-10T00:00:00Z